powder for solution for injection/infusion
Sponsors
University College London, Takeda Development Center Americas Inc., University Of Oxford, Replimune Inc., Erasca Inc.
Conditions
Advanced Classical Hodgkin LymphomaAdvanced MelanomaPatients with High Risk NeuroblastomaPneumoniaUnresectable or metastatic NRAS mutant cutaneous melanoma stage IA/IIA Hodgkin lymphoma
Phase 3
RADAR: A randomised phase III trial with a PET response adapted design comparing ABVD +/- ISRT with A2VD +/- ISRT in patients with previously untreated stage IA/IIA Hodgkin lymphoma
RecruitingCTIS2022-500031-37-00
Start: 2024-04-08Target: 289Updated: 2025-06-23
RANDOMISED EVALUATION OF COVID-19 THERAPY (RECOVERY)
RecruitingCTIS2023-507441-29-00
Start: 2024-02-29Target: 1590Updated: 2025-11-10
A Randomized, Open-label, Phase 3 Trial of A+AVD Versus ABVD as Frontline Therapy in Patients With Advanced Classical Hodgkin Lymphoma
Active, not recruitingCTIS2023-506419-16-00
Start: 2013-01-08Target: 448Updated: 2025-12-15
A RANDOMIZED, OPEN-LABEL PHASE 3 STUDY IN PATIENTS WITH PREVIOUSLY TREATED UNRESECTABLE OR METASTATIC NRAS MUTANT CUTANEOUS MELANOMA COMPARING THE COMBINATION OF NAPORAFENIB + TRAMETINIB TO PHYSICIAN’S CHOICE OF THERAPY (DACARBAZINE, TEMOZOLOMIDE OR TRAMETINIB MONOTHERAPY) WITH A DOSE OPTIMIZATION LEAD-IN [SEACRAFT-2]
RecruitingCTIS2024-511404-17-00
Start: 2024-10-07Target: 294Updated: 2026-01-07
High-Risk Neuroblastoma Study 2 of SIOP-Europa-Neuroblastoma (SIOPEN) “Randomized, international and multicentric phase 3 study that evaluates and compares 2 treatment strategies in 3 therapeutic phases (induction, high-dose chemotherapy and radiotherapy) for patients with high-risk neuroblastoma and introduces chemoimmunotherapy for patients with insufficient metastatic response after induction chemotherapy
RecruitingCTIS2024-514917-36-00
Start: 2024-11-21Target: 719Updated: 2025-01-17
A Randomized, Controlled, Multicenter, Phase 3 Clinical Study Comparing Vusolimogene Oderparepvec in Combination with Nivolumab Versus Treatment of Physician’s Choice in Patients with Advanced Melanoma That Has Progressed on an Anti-PD-1 and an Anti-CTLA-4 Containing Treatment Regimen [IGNYTE-3]
RecruitingCTIS2023-508612-29-00
Start: 2025-11-07Target: 193Updated: 2025-11-04